0
0
June 2, 2025
Despite longstanding concerns about the tobacco industry’s influence on science, research funded by tobacco companies continues to be published in some of the world’s most respected medical journals, according to a recent investigation by The Investigative Desk and The BMJ.
The investigation highlights that, although the tobacco industry has a well-documented history of manipulating scientific research, only a minority of leading medical journals have explicit policies banning studies funded wholly or partially by tobacco companies. This loophole has allowed hundreds of studies with direct or indirect tobacco industry ties to appear in peer-reviewed literature.
Complex Funding Webs Complicate Oversight
One of the major challenges identified is the difficulty in tracing funding sources. Tobacco companies have diversified their investments, often funding research through front groups, subsidiaries, or by acquiring companies in the pharmaceutical and health technology sectors. These investments frequently include treatments for diseases caused or worsened by smoking, such as lung cancer, heart disease, and asthma.
The investigation reviewed the policies of 40 leading journals across general medicine, respiratory medicine, oncology, and cardiology. Only 8 journals (20%) had policies prohibiting tobacco-funded research. Respiratory medicine journals were most likely to have such policies, while oncology and cardiology journals lagged behind. Even when policies exist, enforcement is complicated when funding comes from subsidiaries or organizations linked to tobacco companies.
Recent Cases Highlight Ongoing Issues
For example, a study funded by Vectura—a pharmaceutical company acquired by Philip Morris International (PMI) in 2021—was published in a leading respiratory journal because the grant was awarded before the acquisition. In another case, BMJ Open retracted a paper after it was revealed that the funder received support from the Foundation for a Smoke-Free World, which is fully funded by PMI.
Calls for Stronger Action
Experts argue that the medical community must take a firmer stance. Ruth Malone, professor at the University of California and former editor-in-chief of BMJ’s Tobacco Control journal, emphasized the need for journals, institutions, and professionals to reject tobacco industry money outright. “Anyone who understands the history, extent and nature of the epidemic and the tobacco industry’s strategic efforts to divide the public health community knows that industry money should be rejected,” she stated.
Nicholas Hopkinson, professor of respiratory medicine at Imperial College London, added that researchers should sever ties with companies once they are acquired by tobacco interests, to avoid contributing to the industry’s profits.
BMJ Updates Its Policy
In response to these concerns, The BMJ has updated its 2013 tobacco policy. The revised policy excludes not only research funded by the tobacco industry but also work where authors have personal financial ties to tobacco companies. Editors hope this will create a stronger firewall between the industry and scientific content, ensuring greater independence and trustworthiness in published research.
Disclaimer:
This article is based on information from a report by The Investigative Desk and The BMJ, as summarized by News-Medical.net. The findings and opinions described reflect the sources cited and do not constitute medical advice. Readers are encouraged to consult original sources and professional guidance for further information.
Citations:
